Biden Vs. Trump 2024 Election Polls: Biden Approval Rating Hits New Low—But Trump’s Lead Is Mostly Unchanged, Survey Showson Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech soaring during premarket trading and strengthening the British drugmaker’s vaccine portfolio as it tries to compete with the likes of Moderna, Pfizer and BioNTech.
The British drugmaker said it would pay an additional €1.05 billion upon reaching various development, regulatory and sales milestones for the shots, as well as royalties from sales. The shots for COVID and flu are in mid stage clinical trials and the deal could see GSK regularly update vaccines to combat seasonal variants and potentially developAvailable data for all vaccine candidates suggest they could be “best-in-class new vaccines,” GSK said.
GSK’s chief scientific officer Tony Wood said the company is “excited about our flu/COVID-19 programmes and the opportunity to develop best-in-class mRNA vaccines to change the standard of care” and the company told Reuters the deal willShares for GSK during trading hours in London were flat Wednesday morning but shares for Nasdaq listed CureVac were up around 25% during premarket trading and CEO Alexander Zehnder said the deal strengthens the company’s “financial position and enables us to...
Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you'll always know the biggest stories shaping the day’s headlines. Text “Alerts” to 335-0739 or sign upOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.